Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    National Security
    Science & Regulatory
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    .
    Human Health
    Startups
    .
    Non-R&D Companies
    Member Savings
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Investor Forum
    BIO Asia-Taiwan

    July 15-19, 2026
    Taipei, Taiwan

    BIO Patient & Health Advocacy Summit
    BIO Patient Advocacy Changemakers Event

    October 22-23, 2026
    Washington, D.C

    BIO Asia-Taiwan
    BIO Europe

    November 9-11, 2026
    Cologne, Germany

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyNational SecurityScience & RegulatoryAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3232 results found
Expand All
Apply All
3232 results found

Testimony of Kay Holcombe, Senior Vice President, Science Policy, Biotechnology Innovation Organization
Share
Letters, Testimony & Comments  •  March 2, 2017
What an honor it is to speak to you today on behalf of the Biotechnology Innovation Organization (BIO) about the Biosimilars User Fee Act reauthorization. This Committee planted the seed that has grown into multiple user fee programs that provide FDA with a significant portion of the resources it needs to ensure that patients have timely access to safe and effective new drugs and biologics, generic drugs, biosimilars, and medical devices. This Committee also tilled the ground and successfully produced, with an overwhelming bipartisan House vote, the legislation that established an FDA pathway for the approval of biosimilars – the Biologics Price Competition and Innovation Act (BPCIA). BIO was an early and strong supporter of this legislation to create a facilitated and balanced pathway for greater competition in the biologics marketplace.
Read More

BIO Presents Sen. John Thune (R-S.D.) Legislator of the Year Award
Share
Press Release  •  February 28, 2017
The Biotechnology Innovation Organization (BIO) today presented Senator John Thune (R-S.D.) its Industrial & Environmental Section Legislator of the Year Award, recognizing the Senator’s steadfast commitment to growing South Dakota’s and the nation’s biobased economy.
Read More

BIO Submits Comments to EMA on Strategies to Identify and Mitigate Risks for First-In-Human and Early Clinical Trials with Investigational Medicinal Products
Share
Letters, Testimony & Comments  •  February 28, 2017
The Biotechnology Innovation Organization (BIO) thanks the European Medicines Agency (EMA) for the opportunity to submit comments on the “Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.” 
Read More

BIO's Testimony in Opposition to Maryland's House Bill 666
Share
Letters, Testimony & Comments  •  February 27, 2017
Patrick Plues, BIO’s Vice President, State Government Affairs, testified before the Maryland House in opposition to House Bill 666, which would require biopharmaceutical manufacturers to disclose specific information on cost inputs for specific drugs and to provide 60-day prior notice of any anticipated price increase for products priced over a certain threshold.
Read More

BIO Submits Amicus Brief in Wi-Fi One, LLC v. Broadcom Corporation (U.S. Court of Appeals for the Federal Circuit)
Share
Amicus Brief  •  February 23, 2017
BIO Submits Brief of Amicus Curiae in Wi-Fi One, LLC v. Broadcom Corporation (U.S. Court of Appeals for the Federal Circuit)
Read More

BIO and Croplife International Submit Amicus Brief in Impression Products Inc. v. Lexmark International Inc. (U.S. Supreme Court)
Share
Amicus Brief  •  February 23, 2017
BIO and Croplife International Submit Brief of Amicus Curiae in Impression Products Inc. v. Lexmark International Inc. (Supreme Court of the United States)
Read More

BIO Submits Comments on EPA’s Proposed Denial of Petitions for Rulemaking to Change the RFS Point of Obligation
Share
Press Release  •  February 22, 2017
In BIO’s view, granting the petitions to change the point of obligation would create unnecessary regulatory uncertainty and fail to further the statutory goals of the Renewable Fuel Standard (“RFS”) program.
Read More

Nominations Now Open for the BIO George Washington Carver Award for Innovation in Industrial Biotechnology
Share
Press Release  •  February 22, 2017
The ninth annual George Washington Carver Award will recognize an individual who has made a significant contribution to building the biobased economy by applying industrial biotechnology to create sustainable and environmentally sustainable products. The Biotechnology Innovation Organization (BIO) will begin accepting nominations for the Award today, February 22, 2017. 
Read More

BIO Submits Comments on EPA Renewables Enhancement and Growth Support Rule
Share
Press Release  •  February 16, 2017
The Biotechnology Innovation Organization (BIO) today submitted comments on the Environmental Protection Agency’s recently proposed Renewables Enhancement and Growth Support (REGS) Rule. BIO supports EPA’s ongoing efforts to improve the efficiency and effectiveness of the federal Renewable Fuel Standards (RFS).
Read More

BIO Comments on EPA’s Renewables Enhancement and Growth Support (REGS) Proposed Rule
Share
Letters, Testimony & Comments  •  February 16, 2017
BIO supports EPA’s ongoing efforts to improve the efficiency and effectiveness of the federal Renewable Fuel Standard (“RFS”) program, which was created by Congress, with bipartisan support, in statutory provisions that President George W. Bush signed into law as part of the Energy Policy Act of 2005 and Energy Independence and Security Act of 2007.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 300
  • 301
  • 302
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO Investment and Growth Summit
BIO Partnering™ for Oncology
BIO International Convention
BIO Partnering™ at JPM Week
BIO Patient Advocacy Changemakers Events
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2026 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO